Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
E grade · PMID 42021568
View analysis →E grade · PMID 41974545
View analysis →E grade · PMID 41962180
View analysis →E grade · PMID 41908734
View analysis →E grade · PMID 41952419
View analysis →E grade · PMID 41977827
View analysis →E grade · PMID 41959636
View analysis →E grade · PMID 41942682
View analysis →E grade · PMID 41940308
View analysis →E grade · PMID 41924697
View analysis →Comprehensive review of hydrogel-based brain–machine interface materials, design, and integration strategies emphasizing their mechanical, electrical, and biocompatible properties and discussing invasive/noninvasive systems, clinical translation, and applications including Parkinson’s disease.
Hydrogel-enabled BMIs promise more compliant, long-lasting neural recording and stimulation interfaces that could reduce inflammation and enable reliable chronic sensing and closed-loop neuromodulation important for advancing Parkinson’s diagnostics and therapies.
Protocol for a randomized feasibility study comparing computational, patient-specific STN-DBS programming based on anatomy and structural connectivity to conventional monopolar review programming in Parkinson's disease.
This work is clinically translational: if safe and practical, connectivity-guided individualized programming could shorten time-to-optimal DBS settings and reduce stimulation side effects, improving therapeutic delivery though it does not target underlying disease mechanisms.
This polysomnography study shows that ORP measures of sleep depth—particularly the overnight change in ORP (ORPdiff)—differ between PD and OSA groups and that smaller ORPdiff (less restorative sleep) is associated with worse cognition and greater non-motor symptoms in Parkinson's disease.
Suggests ORP-derived sleep-depth metrics could serve as objective biomarkers of cognitive vulnerability and non-motor burden in PD and highlights sleep restoration as a potentially modifiable target for therapeutic strategies, although causal mechanisms and intervention data are lacking.
Large retrospective cohort (n=405) of young-onset Parkinson disease patients shows both GPi and STN deep brain stimulation improve motor symptoms at 1 and 5 years; STN produced greater medication reduction and modest motor benefit while GPi better reduced dyskinesia and motor fluctuations.
This study informs clinical decision-making about DBS target selection in young-onset PD with actionable, long-term outcome data, but it offers limited mechanistic or drug-discovery insights relevant to molecular therapeutic development.
This immunohistochemical study reports widespread neuronal mislocalisation (nuclear loss and cytoplasmic aggregation) of the RNA-binding protein hnRNP K across multiple brain regions in neurodegenerative diseases and aging, with prominent involvement of basal ganglia and a significant correlation…
Points to hnRNP K mislocalisation as a potential mechanistic contributor or biomarker linked to motor dysfunction in Parkinson’s and related disorders, highlighting a novel RNA-processing–related target for validation and region-specific therapeutic investigation, though findings are exploratory…
Scoping review of 60 studies surveying machine- and deep-learning approaches (notably CNNs and LSTMs) using wearable inertial sensors to detect and predict freezing of gait and discussing integration into real-time closed-loop systems.
Highlights a translational pathway for digital biomarkers and real‑time detection that can enable adaptive therapies (e.g., closed‑loop DBS, exoskeletons) and better clinical endpoints, but offers limited direct molecular or drug‑discovery insights.
Systematic review of 41 studies evaluating single-point lower-trunk magneto-inertial sensors for gait and TUG assessment in Parkinson's and parkinsonisms found moderate-quality evidence (12% high-quality), good reporting of technical aspects but poor clinical characterization and protocol…
The paper supports single-point mIMUs as a promising, low-cost digital biomarker for monitoring mobility, stratifying patients, and serving as trial endpoints in PD, but emphasizes that standardization and better clinical reporting are needed before wide adoption for therapeutic development.
Systematic review and meta-analysis of 42 studies (2,111 pwPD) found greater gait asymmetry in Parkinson's disease—especially in step length, step time, and swing time—with swing time asymmetry most sensitive and partially responsive to dopaminergic medication.
Highlights swing time asymmetry as a measurable, treatment-responsive clinical biomarker that could improve phenotyping and outcome measures for trials and targeted gait interventions, though it offers limited mechanistic or direct therapeutic targets.
This study synthesizes clinician and patient priorities—highlighting tremor, rigidity, bradykinesia, global motor function, hand/mobility difficulties, depression, and fatigue—to inform the design of a smartphone/wearable digital endpoint (PD-FIDI).
By defining clinically and patient-relevant, remotely measurable outcomes, the paper supports development of validated digital endpoints that can improve trial sensitivity and outcome measurement for Parkinson's therapeutics, though it does not address disease mechanisms or interventions directly.
This review synthesizes advances in ocular motor and pupillary biomarkers (oculomics/oculometrics), describing saccadic, pursuit, convergence, and pupillometry abnormalities in Parkinson's disease and proposing eye-tracking and VR-based paradigms for diagnosis and monitoring.
Ocular biomarkers are noninvasive, scalable tools that could improve early detection, patient stratification, and sensitive outcome measures for Parkinson's trials, though the review offers limited direct therapeutic or mechanistic insights and stresses need for large-scale validation.
This systematic review and meta-analysis found that Jitter (variation in fundamental frequency) is significantly increased in patients with Parkinson's disease, Alzheimer's disease, and depression, while Shimmer (amplitude variation) was not consistently different, supporting Jitter as a potential…
A validated, noninvasive speech-based biomarker like Jitter could facilitate screening, remote monitoring, and patient stratification in Parkinson's clinical studies, but it offers little direct insight into molecular therapeutic targets.
Retrospective single-center review of 397 DBS procedures (388 patients) identifying older age and anticoagulant use as predictors of prolonged hospital stay, and infections and skull-mounted implants as leading causes of six-month readmissions.
Useful for perioperative risk stratification, prehabilitation, and resource planning to reduce complications and costs after DBS, but offers minimal mechanistic or therapeutic-discovery insight for Parkinson's disease drug development.
Systematic review of 89 studies (predominantly in Parkinson's disease) characterizing wearable sensor types, placements (ankle common), and machine-learning algorithms for fall detection and calling for standardized, real-world validation.
Although it doesn't address molecular or therapeutic mechanisms, the paper is useful for Parkinson's drug development because robust, validated wearable fall-detection tools can supply objective real-world endpoints, safety monitoring, and patient stratification to improve clinical trials and care.
Systematic review of eight small, mostly single-center studies (n=555) applying non-imaging clinical-data machine learning (mostly SVM and k-NN) to classify symptoms or predict DBS outcomes in Parkinson's, finding exploratory, heterogeneous methods with limited external validation.
Highlights potential for ML to improve DBS patient stratification and outcome prediction but provides little mechanistic or therapeutic insight for Parkinson's drug discovery and is not yet clinically translatable.
Retrospective audit of 26 atypical parkinsonian patients found orthoptic oculomotor and eye-tracker assessment agreed with final neurology diagnoses in ~80.8% of cases for distinguishing suspected PSP from non-PSP.
This work aids clinical phenotyping and early patient selection for trials or observational studies but provides little mechanistic or therapeutic insight, so its direct value for Parkinson's drug discovery is limited.
Retrospective review of 3,286 PD/ET patients at a tertiary movement disorders center (2012–2022) found 12.1% underwent DBS, with higher odds of surgery among Medi‑Cal recipients and low neighborhood SES and lower odds among younger patients, single individuals, and Asian patients, suggesting…
Although not mechanistic, the paper is valuable for therapeutic implementation because it identifies access and referral disparities that can influence equitable delivery of advanced PD therapies, clinical trial recruitment, and prioritization of outreach or systems-level interventions.
Qualitative care-pathway study of SMaRT-PD, a home-based remote monitoring and CDSS for Parkinson’s, reporting clinician support for benefits (patient empowerment, earlier identification, clinic efficiency) alongside concerns about reduced face-to-face contact and administrative/clinical…
While it offers little direct mechanistic or drug-discovery insight, the work is valuable for clinical translation—informing remote monitoring, outcome capture, and resource allocation that can indirectly accelerate therapeutic evaluation and implementation.
Cross-sectional and Mendelian-randomization analyses indicate longer leukocyte telomere length is associated with better cognitive performance and causally linked to lower risk of all-cause dementia, Alzheimer’s and vascular dementia, but show no causal association with Parkinson’s disease.
The study supports telomere length as an aging-related biomarker and possible target for dementia prevention, but provides limited direct, actionable insight for Parkinson’s therapeutic discovery.
Small qualitative study (n=14, ages 67–92, including some participants with Parkinson disease) found a walking-based mobile exergame increased motivation, goal-setting, feedback, self-monitoring, and routine integration but had limited social feature uptake and varied digital literacy.
This work is useful for designing interventions to increase physical activity and adherence in people with Parkinson's (symptomatic/supportive care and trial engagement), but it has minimal direct relevance to therapeutic discovery because it provides no mechanistic, biomarker, or disease-modifying…
Retrospective chart review found Chinese immigrants with idiopathic Parkinson's in NYC had a mean reported diagnostic latency of ~20 months, with gait/postural-onset cases experiencing longer delays than tremor-dominant cases.
Although not mechanistic, the study identifies sociocultural and healthcare-access barriers that delay diagnosis and treatment initiation, which can affect clinical outcomes and equitable recruitment into therapeutic trials.
